On August 4, 2025, 180 Life Sciences Corp. completed a private placement, selling 142,882,173 shares of common stock at $2.65 each, and 17,495,849 pre-funded warrants to certain investors; additionally, Dr. Lawrence Steinman resigned from the board and two new directors, Andrew Suckling and Crystal Heter, were appointed as part of the changes.